ARCHETYPE Intravitreal injection details (openEHR-EHR-CLUSTER.intravitreal_injection_details.v0)

ARCHETYPE IDopenEHR-EHR-CLUSTER.intravitreal_injection_details.v0
ConceptIntravitreal injection details
DescriptionDetails about intravitreal injection procedure.
UseEither to provide details about the procedure whenever a intravitreal injection is scheduled, or to register the consequent realization of that procedure.
PurposeProvide details about intravitreal injection.
References- Avery RL, Bakri SJ, Blumenkranz MS, Brucker AJ, Cunningham ETJ, D'Amico DJ, et al. Intravitreal injection technique and monitoring: Updated guidelines of an expert panel. Retina (Philadelphia, Pa) 2014; 34:S1-S18.
- Dossarps D, Bron AM, Koehrer P, Aho-Glélé LS, Creuzot-Garcher C, net F, et al. Endophthalmitis After Intravitreal Injections: Incidence, Presentation, Management, and Visual Outcome. American journal of ophthalmology 2015; 160(1):17-250.
- Fagan XJ, Al-Qureshi S. Intravitreal injections: a review of the evidence for best practice. Clinical & experimental ophthalmology 2013; 41(5):500-7.
- Nentwich MM, Yactayo-Miranda Y, Schwarzbach F, Wolf A, Kampik A, Mino de Kaspar H. Endophthalmitis after intravitreal injection: decreasing incidence and clinical outcome-8-year results from a tertiary ophthalmic referral center. Retina (Philadelphia, Pa) 2014; 34(5):943-50.
- Website of the OpenEyes project: http://www.openeyes.org.uk/
Copyright© openEHR Foundation
AuthorsAuthor name: Aitor Eguzkitza
Organisation: Universidad Pública de Navarra & Complejo Hospitalario de Navarra
Email: aitor.eguzkiza@unavarra.es
Date originally authored: 2015-06-16
Other Details LanguageAuthor name: Aitor Eguzkitza
Organisation: Universidad Pública de Navarra & Complejo Hospitalario de Navarra
Email: aitor.eguzkiza@unavarra.es
Date originally authored: 2015-06-16
Other Details (Language Independent)
  • Licence: This work is licensed under the Creative Commons Attribution-ShareAlike 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-sa/3.0/.
  • Custodian Organisation: openEHR Foundation
  • References: - Avery RL, Bakri SJ, Blumenkranz MS, Brucker AJ, Cunningham ETJ, D'Amico DJ, et al. Intravitreal injection technique and monitoring: Updated guidelines of an expert panel. Retina (Philadelphia, Pa) 2014; 34:S1-S18. - Dossarps D, Bron AM, Koehrer P, Aho-Glélé LS, Creuzot-Garcher C, net F, et al. Endophthalmitis After Intravitreal Injections: Incidence, Presentation, Management, and Visual Outcome. American journal of ophthalmology 2015; 160(1):17-250. - Fagan XJ, Al-Qureshi S. Intravitreal injections: a review of the evidence for best practice. Clinical & experimental ophthalmology 2013; 41(5):500-7. - Nentwich MM, Yactayo-Miranda Y, Schwarzbach F, Wolf A, Kampik A, Mino de Kaspar H. Endophthalmitis after intravitreal injection: decreasing incidence and clinical outcome-8-year results from a tertiary ophthalmic referral center. Retina (Philadelphia, Pa) 2014; 34(5):943-50. - Website of the OpenEyes project: http://www.openeyes.org.uk/
  • Original Namespace: org.openehr
  • Original Publisher: openEHR Foundation
  • Custodian Namespace: org.openehr
  • MD5-CAM-1.0.1: F618898F7B3503AA482C4B6195535636
  • Build Uid: cdb9dd49-37cd-4477-b211-7a4b7c622d00
  • Revision: 0.0.1-alpha
Keywordsintraocular injection, intravitreal injection
Lifecyclein_development
UIDb6d9d7b6-bc4f-4352-b8fe-998a6841917a
Language useden
Citeable Identifier1013.1.2016
Revision Number0.0.1-alpha
items
LateralityLaterality: Eyes treated in the same sitting.
  • Left [IVT injection on the left eye.]
  • Right [IVT injection on the right eye.]
  • Bilateral [IVT bilateral injection.]
Clinical SettingClinical Setting: Allocation where the intravitreal injection takes place.
  • Office setting [Intravitreal injections performed in ophthalmologist's office.]
  • Treatment room [Intravitreal injections performed in a dedicated treatment room.]
  • Operating room [Intravitreal injections performed in the operating room.]
ContraindicationsContraindications: Identifies possible contraindications (if any) to be considered before conducting ITV injections.
  • Ocular hipertension/glaucoma [Patients with preeexisting ocular hipertension/glaucoma.]
  • Previous conditions/surgeries [Preexisting ocular conditions/previous ocular surgeries.]
  • Recent surgery [Recent postcataract surgery patients.]
  • Complex conditions [Complex medical or ocular conditions.]
  • Anticoagulation [Patients on anticoagulation.]
  • Allergy [Allergy to Povidone–Iodine.]
  • Infection [Active external infection, including active infection in blepharitis.]
  • Abnormalities [Eyelid, adnexal, and ocular surface abnormalities.]
AnaestheticAnaesthetic: Details concerning the anaesthetic prior to the procedure.
Anaesthetic TypeAnaesthetic Type: Type of anesthesia chosen.
  • Topical [Topical anaesthesia.]
    [SNOMED-CT::6064005 | Topical route]
  • Drops [Anaesthetic agent in drops form.]
  • Gel [Anaesthetic agent in gel form.]
  • Injection [Anaesthesia by injection.]
Anaesthetic RouteAnaesthetic Route: Route chosen to apply the anesthesia.
Anaesthetic AgentAnaesthetic Agent: Anesthetic agent.
Constraint:
Compounds for local anaesthesia
[Attach a list that restricts the anesthetic agents, to those compounds used in ophthalmology to anaesthetize patients prior to intravitreal injection.]
PreparationPreparation: Details about preparation of the intervention.
Sterile DrapeSterile Drape: Use or not of a sterile drape before injection.
SpeculumSpeculum: Use of speculum or on the contrary manual eye lid retraction, to prevent contact of the eyelashes and eyelid margins with both the injection site and the injection needle.
Sterile GlovesSterile Gloves: Use of sterile or nonsterile gloves during the intervention.
Surgical MasksSurgical Masks: Use of surgical masks by clinicians and patients, or on the contrary, do not use mask but minimize speaking to reduce infection risk during procedure.
Monitor IOPMonitor IOP: *
Anti-infective on EyelidsAnti-infective on Eyelids: Application or not of anti-infective agent to the eyelids, including the eyelid margins and eyelashes.
Dilation RequiredDilation Required: Need or not of pupillary dilation prior to the surgical intervention.
Pre Injection Skin CleanserPre Injection Skin Cleanser: Anti-infective agent used for skin cleanse.
Constraint:
Anti-infective agents in ophthalmology
[List of anti-infective agents available for opthalmic use.]
Pre Injection Conjunctival CleanserPre Injection Conjunctival Cleanser: Anti-infective agent used as antiseptic.
Constraint:
Anti-infective agents in ophthalmology
[List of anti-infective agents available for opthalmic use.]
Pre Injection IOP Lowering Therapy RequiredPre Injection IOP Lowering Therapy Required: Select if pre Injection IOP lowering therapy is required.
Assumed value: false
Pre Injection IOP Lowering TherapyPre Injection IOP Lowering Therapy: Therapy chosen to lower patient's IOP prior to injections.
Intravitreal InjectionsIntravitreal Injections: Details about application of injections.
Compound InjectedCompound Injected: Compound contained within the intravitreal injection.
Constraint:
List of compounds validated for intraocular injection
[Compounds administered in ophthalmology in the form of intraocular injection.]
Injection SiteInjection Site: Distance in mm of the needle posterior to the limbus between the vertical and horizontal rectus muscles.
Property: Length
Units: 2.5..4.5 mm
Limit decimal places: 1
Number of injectionsNumber of injections: Number of injections involved in the current intervention.
min: >=1
<br/>Assumed value1
Batch NumberBatch Number: Batch number of the injections used.
Batch Expiry DateBatch Expiry Date: Expiry date for the batch of injections used.
Full Date
Post InjectionPost Injection: Details about procedures after intravitreal injections to guarantee patient's safety.
Post Injection IOP Lowering Therapy RequiredPost Injection IOP Lowering Therapy Required: Select if IOP lowering is required after injection.
Assumed value: false
Post Injection IOP Lowering TherapyPost Injection IOP Lowering Therapy: Therapy chosen to lower patient's IOP after injections.
  • Apraclonidine 0.5% [Apraclonidine (trade name Iopidine Eye) 0.5% intra-ocular solution.]
  • Apraclonidine 1% [Apraclonidine (trade name Iopidine Eye) 1% intra-ocular solution.]
  • Acetazolamide 250mg [Acetazolamide (trade name Diamox) 250mg m/r capsule.]
  • Acetazolamide 500mg [Acetazolamide (trade name Diamox) 500mg m/r capsule.]
Post Injection examinationPost Injection examination: Routine examination to check the patient's status after the therapy.
Counting FingersCounting Fingers: Evaluation about if the patient is able to count fingers or not.
IOP CheckedIOP Checked: Intraocular pressure measurement is recommended or not.
Post Injection DropsPost Injection Drops: Details about a preventive treatment of antibiotics after intravitreal injections.
Include:
openEHR-EHR-CLUSTER.medication_admin.v1 and specialisations
ComplicationsComplications: Possible complications due to intravitreal injections.
  • Infectious endophthalmitis [Infectious endophthalmitis.]
  • Subconjunctival haemorrage [Subconjunctival haemorrage.]
  • Conjunctival damage [Conjunctival damage (e.g. tear).]
  • Corneal abrasion [Corneal abrasion.]
  • Lens damage [Lens damage.]
  • Retinal damage [Retinal damage.]
  • Other [Other complication not provided in the list.]
Other contributorsJose Andonegui Navarro, Complejo Hospitalario de Navarra, Spain
Luis Serrano Arriezu, Institute of Smart Cities & Universidad Pública de Navarra, Spain
Gustavo Bacelar-Silva, Healthcare Designs, Brazil
Yves Genevier, Privantis, Switzerland
Thomas Pedersen Bærland, DIPS, Norway
Heather Leslie, Ocean Informatics, Australia
Ian McNicoll, freshEHR Clinical Informatics, United Kingdom
Translators